Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaFRA:BA3 -0.70%78 EV-to-EBITDA is 35.64 as of Aug. 29, 2026, which is 11% below its 10-year median of 40.09. GuruFocus rates FRA:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.15 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 523 Medical Devices & Instruments companies, Azenta ranks worse than 83.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Azenta's enterprise value is €1,005.5 Mil.
Azenta's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €28.2 Mil. Therefore, Azenta's EV-to-EBITDA for today is 35.64.
The historical rank and industry rank for Azenta's EV-to-EBITDA or its related term are showing as below:
FRA:BA3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1441.9 Med: 40.09 Max: 1125.91
Current: 35.6
During the past 13 years, the highest EV-to-EBITDA of Azenta was 1125.91. The lowest was -1441.90. And the median was 40.09.
FRA:BA3's EV-to-EBITDA is ranked worse than 83.37% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs FRA:BA3: 35.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-29), Azenta's stock price is €28.40.
Azenta's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.397. Therefore, Azenta's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Azenta's share price for today is €28.40.
Azenta's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.397.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Azenta's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BA3 vs KMTS, STAA, BLFS: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Azenta's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Azenta's EV-to-EBITDA falls into.
Azenta's current Enterprise Value is €1,005.5 Mil.
Azenta's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azenta (FRA:BA3) has a EV-to-EBITDA of 35.64 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Azenta. This is 11% below median its historical median of 40.09. According to the industry distribution chart, Azenta ranks #436 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 83.4%.
Is Azenta's EV-to-EBITDA too high?
Azenta's current EV-to-EBITDA of 35.64 is 11% below median its 10-year median of 40.09. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.62. Azenta's value of 35.64 is 143.8% above this industry median. Based on the distribution chart, Azenta ranks #436 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's EV-to-EBITDA compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #436 out of 523 companies for EV-to-EBITDA. This places Azenta in the lower half of its industry. The industry median EV-to-EBITDA is 14.62. Azenta's value of 35.64 is 143.8% above this benchmark. While the company's 10-year median is 40.09 vs. the industry median of 14.62, Azenta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current EV-to-EBITDA of 35.64 is 143.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Azenta. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current EV-to-EBITDA is 35.64, which is 11% below median its own 10-year median of 40.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (FRA:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.15, compared to a current price of €28.40 — trading 37.1% below its estimated fair value. The current EV-to-EBITDA is 35.64, which is 11% below median its 10-year median of 40.09 and 143.8% above the Medical Devices & Instruments industry median of 14.62. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Azenta (FRA:BA3), the current EV-to-EBITDA is 35.64 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (FRA:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.40 is trading 37.1% below its estimated GF Value™ of €45.15.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for FRA:BA3:
EV-to-EBITDA: 35.64 (11% below median its 10-year median of 40.09)
GF Value™: €45.15 vs. price of €28.40 (37.1% below fair value)
Industry Position: 143.8% above the Medical Devices & Instruments median (#436 of 523)
No single metric tells the full story. See the FRA:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for FRA:BA3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BA3 has been successfully added to your 
